Kodiak Sciences Stock Surged After Phase 3 Results

The company reported positive data for two wet age-related macular degeneration treatments, triggering a 600% annual rise.

Updated on Oct. 5, 2026 in Biotech

Isometric editorial illustration of a complex molecular structure made of interconnected spheres, representing biopolymer drug technology. — Kodiak Sciences shares surged 600% over the past year following positive Phase 3 results for experimental retinal disease treatments. AI Illustration. Upload story photo >

Live Poll

Is now a good time for you to invest in clinical-stage biotech stocks?

Kodiak Sciences saw its stock price climb 600% over the past twelve months following positive Phase 3 results for experimental treatments Zenkuda and tabirafusp-ted. These results indicate the therapies met primary endpoints in treating wet age-related macular degeneration.

Why it matters

The company's clinical success in retinal disease treatment has catalyzed significant investor interest despite ongoing quarterly financial losses. This momentum sets the stage for a potential regulatory shift as the firm prepares to move toward commercialization.

The Phase 3 DAYBREAK study demonstrated that 54% of patients treated with Zenkuda achieved a six-month dosing interval at the one-year mark. These results were measured against existing aflibercept benchmarks.

The players

Kodiak Sciences

A biotech firm developing retinal disease therapies using biopolymer conjugate technology.

The details

Kodiak Sciences employs biopolymer conjugates — large, complex molecules designed to extend the duration of drug activity — to achieve a treat-to-dryness dosing approach. This method seeks to maintain the absence of retinal fluid by titrating doses based on individual patient response rather than a fixed schedule. The company intends to leverage these outcomes to support a multi-indication biologics license application, a formal request for FDA approval to market a biological product.

Q2 2026: The company reported a net loss of $65.6 million.
September 28, 2026: The Phase 3 DAYBREAK study results were delivered.
October 2, 2026: KOD stock closed at $94.45.
Q4 2026: The company plans to file a biologics license application for Zenkuda.
December 2026: Phase 3 results for KSI-101 are expected.

The Tech Race

Kodiak Sciences is positioning its biopolymer-based therapies to compete against established anti-VEGF treatments for retinal diseases. The recent clinical success places their pipeline in direct contention with the current standard of care for wet age-related macular degeneration.

Patients currently managing wet age-related macular degeneration may see a shift in treatment frequency if the treat-to-dryness approach gains regulatory approval. Clinical availability currently remains limited to research study participants until the pending biologics license application is processed.

The takeaway

The surge in Kodiak Sciences stock reflects market optimism toward their proprietary dosing methodology. Investors and patients should track the upcoming biologics license application for Zenkuda in Q4 2026 as a primary indicator of clinical viability.